Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2003
05/15/2003US20030092623 Inducing proliferation of endothelial cells; use of Bv8 antagonists to treat testicular cancer and hormone dependent tumors; Bv8 is a small protein originally isolated from the skin secretions of the frog Bombina variegata
05/15/2003US20030092606 Formulations for amylin agonist peptides
05/15/2003US20030092601 Microcompetition and human disease
05/15/2003US20030092180 Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
05/15/2003US20030092176 Ependymal neural stem cells and method for their isolation
05/15/2003US20030092133 Interleukins-21 and 22
05/15/2003US20030092130 DNA encoding polypeptides having interferon-gamma inducing activity
05/15/2003US20030092120 Novel human K+ ion channel and therapeutic applications thereof
05/15/2003US20030092069 Hollow nanoparticle for use in the transfer of biopolymer into cells
05/15/2003US20030092054 Protein complexes and assays for screening anti-cancer agents
05/15/2003US20030092011 Human cDNAs and proteins and uses thereof
05/15/2003US20030091996 Apoptin-associating protein
05/15/2003US20030091977 Assessment method
05/15/2003US20030091974 Detecting compounds capable of exhausting mast cells; culture mast cells, incubate with modulator, measure mast cell death, classify compound
05/15/2003US20030091659 Plant extracts; active materials
05/15/2003US20030091654 Dietetics, antidiabetic agents; using chromium complex
05/15/2003US20030091621 Encapsulated drugs
05/15/2003US20030091620 Transdermal drug delivery systems containing quaternary ammonium salts and methods of using the same
05/15/2003US20030091574 Combination treatment of pancreatic cancer
05/15/2003US20030091570 Analgesics; antiinflammatory agents; analyzing drug as to ability to modulation gene expression
05/15/2003US20030091567 Antiinflammatory agents; anticancer agents
05/15/2003US20030091561 Anticancer agents
05/15/2003US20030091537 Anticancer agents; gene coding immunomoderator cytokine protein
05/15/2003US20030091535 Mutant virus with defective genome; genetic engineering
05/15/2003US20030091518 Mixture containing plant extracts and oils
05/15/2003CA2789407A1 Inhibitor oligonucleotides and their use for specific repression of a gene
05/15/2003CA2669810A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
05/15/2003CA2469818A1 Anticancer compositions
05/15/2003CA2469406A1 Anticancer compositions
05/15/2003CA2466880A1 Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
05/15/2003CA2466516A1 Targeting the reverse mode of the na+/ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
05/15/2003CA2466425A1 Photodynamic therapy for the treatment of hair loss
05/15/2003CA2466391A1 Polyamide modulators of cox2 transcription
05/15/2003CA2466336A1 Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
05/15/2003CA2466334A1 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
05/15/2003CA2466303A1 Selective targeting of apoptotic cells
05/15/2003CA2466284A1 N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
05/15/2003CA2466145A1 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
05/15/2003CA2466138A1 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
05/15/2003CA2466128A1 Antibodies to cd40
05/15/2003CA2466106A1 Methods of treating endometreosis
05/15/2003CA2466083A1 Compositions for the treatment of infectious diseases
05/15/2003CA2466033A1 Method of treating disorder related to high cholesterol concentration
05/15/2003CA2466030A1 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003CA2465953A1 Novel isoforms of vascular endothelial cell growth inhibitor
05/15/2003CA2465952A1 Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium
05/15/2003CA2465945A1 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003CA2465916A1 Treatment of breast cancer
05/15/2003CA2465886A1 Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
05/15/2003CA2465744A1 Use of endothelin receptor antagonists in the treatment of tumour diseases
05/15/2003CA2465713A1 Derivatives of phenoxy-n-'4-(1,1-dioxoisothiazolidin-2-yl)phenyl!-valeramide and other compounds as inhibitors of coagulation factor xa for the treatment of thromboembolic diseases and tumours
05/15/2003CA2465711A1 Aminopyrimidines and pyridines
05/15/2003CA2465695A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
05/15/2003CA2465680A1 Piperazine derivatives having sst1 antagonistic activity
05/15/2003CA2465491A1 Mitotic kinesin inhibitors
05/15/2003CA2465476A1 Methods and compositions for correction of cardiac conduction disturbances
05/15/2003CA2465364A1 Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor
05/15/2003CA2465189A1 Substituted diphenyl heterocycles useful for treating hcv infection
05/15/2003CA2465100A1 Quinazoline derivatives as antitumor agents
05/15/2003CA2465068A1 Quinazoline derivatives as antitumor agents
05/15/2003CA2464765A1 Type 2 cytokine receptor and nucleic acids encoding same
05/15/2003CA2464757A1 Selective antibacterial agents
05/15/2003CA2464685A1 Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
05/15/2003CA2464614A1 Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
05/15/2003CA2464529A1 Method of treating estrogen responsive breast cancer
05/15/2003CA2464470A1 Novel epidermal growth factor protein and gene, and methods of use therefor
05/15/2003CA2464217A1 Antimuscarinic aerosol
05/15/2003CA2464145A1 Polymorphic form of rimonabant, method for preparing it and pharmaceutical compositions containing it
05/15/2003CA2464007A1 Methods for treating ocular neovascular diseases
05/15/2003CA2462502A1 Improved use of antitumoral compound in cancer therapy
05/15/2003CA2462462A1 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
05/15/2003CA2461373A1 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
05/15/2003CA2461183A1 Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
05/15/2003CA2429147A1 Radiosensitivity enhancers, radiosensitivity-enhancing nucleic acids and proteins in cancer radiotherapy
05/14/2003EP1310509A2 Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
05/14/2003EP1310498A2 Pyrazoloquinolinone derivatives as protein kinase C inhibitors
05/14/2003EP1310495A2 Glycidyl amines and their use in the preparation of HIV protease inhibitors
05/14/2003EP1310494A1 PPAR (delta) ACTIVATORS
05/14/2003EP1310493A1 N-adamantylalkyl benzamide derivates as p2x7-receptor antagonists
05/14/2003EP1310491A1 Method for producing 1-substituted-1,2,3-triazole derivative
05/14/2003EP1310490A1 Gpr14 antagonist
05/14/2003EP1310488A1 Fused bicyclic amide compounds and medicinal use thereof
05/14/2003EP1310262A1 Topical composition having undifferentiated plant seed cells and method for using same
05/14/2003EP1309726A2 Rna sequence-specific mediators of rna interference
05/14/2003EP1309721A2 Modulating multiple lineage kinase proteins
05/14/2003EP1309706A2 Modulation of stem cell differentiation
05/14/2003EP1309704A2 Regulation of human membrane-type serine protease
05/14/2003EP1309700A2 Human phosphodiesterases
05/14/2003EP1309699A2 Elongase genes and uses thereof
05/14/2003EP1309697A2 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
05/14/2003EP1309693A2 Anti-dual integrin antibodies, compositions, methods and uses
05/14/2003EP1309692A2 Anti-il-12 antibodies, compositions, methods and uses
05/14/2003EP1309691A2 Anti-tnf antibodies, compositions, methods and uses
05/14/2003EP1309685A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
05/14/2003EP1309682A2 Tetraspan protein and uses thereof
05/14/2003EP1309622A2 Lat peptides and their use in assays for identifying immunosuppressants
05/14/2003EP1309620A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
05/14/2003EP1309609A2 Lactam compounds and their use as inhibitors of serine proteases and method
05/14/2003EP1309596A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases
05/14/2003EP1309595A2 Synthesis of (r)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-h-imidazo(1,2-a) imidazol-2-one
1 ... 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 ... 1564